Bicyclic Glycyl Proline Analogs for Pitt Hopkins Synaptic Rescue
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is currently no cure or treatment specifically for Pitt Hopkins Syndrome (PTHS), a rare genetic condition characterized by significant developmental delays, intellectual disability, and behavioral differences, affecting both males and females, with an estimated prevalence of 1:11,000 individuals in the US population, leading to severe disability and high medical and supportive care costs.
Innovation Solution
The use of bicyclic compounds such as cyclic Glycyl Proline (cG-2-AllylP) and related analogs to treat PTHS by reducing neuroinflammation, normalizing AKT and ERK expression, and restoring IGF-1 levels, mimicking the natural actions of cGP to rescue abnormal dendritic morphology and stimulate protein synthesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bicyclic compounds (cG-2-AllylP and analogs) are administered to treat PTHS, then neuroinflammation is reduced and dendritic morphology is rescued, but the treatment is specific only to TCF4-deficient individuals and does not impact wild-type mice
Solution Approach 1:
The patent applies local quality by making the treatment selectively effective only in TCF4-deficient individuals through targeted molecular mechanisms. The bicyclic compounds specifically rescue abnormal dendritic morphology and restore synaptic function only in neurons lacking functional TCF4, while having no impact on wild-type mice. This selective action resolves the contradiction by providing reliable treatment for the target population while maintaining adaptability through mechanism-based specificity.
2Reliability
If bicyclic compounds are used to rescue abnormal dendritic morphology and stimulate protein synthesis, then synaptic function is restored, but the underlying genetic defect (TCF4 haploinsufficiency) remains uncorrected
Solution Approach 1:
The bicyclic compounds act as molecular intermediaries that bridge the gap between the genetic defect and functional restoration. These compounds do not correct the TCF4 mutation itself but mediate downstream effects by restoring synaptic protein synthesis and dendritic morphology. This intermediary approach resolves the contradiction by providing reliable symptom relief through a complex but targeted molecular mechanism that operates downstream of the genetic defect.
3Reliability
If oral administration of cG-2-AllylP is performed for 6 weeks, then the phenotype of Tcf4+/− knockout mice is rescued, but long-term safety and dosing requirements in humans remain to be established
Solution Approach 1:
The patent applies preliminary action by establishing the effective treatment duration and dosing regimen through preclinical studies in Tcf4+/− knockout mice before human application. The 6-week oral administration protocol was optimized in animal models to achieve complete phenotype rescue, providing a foundation for human clinical trials. This preliminary characterization resolves the contradiction by demonstrating reliable efficacy while identifying the treatment duration needed, though human-specific parameters require further validation.
Data Source
AI summary
Embodiments of this invention provide compounds, compositions, methods, and uses for therapeutic diketopiperazines, including cyclic G-2-Allyl Proline and other cyclic Glycyl Proline compounds to treat Pitt Hopkins Syndrome and symptoms thereof, as well as manufacture of compositions, medicaments including tablets, capsules, liquid formulations, gels, injectable solutions, and other formulations that are useful for treatment of such conditions.